Coexistence of KRAS and BRAF mutations in colorectal cancer: a case report supporting the concept of tumoral heterogeneity
Cell Journal [Yakhteh]. 2017; 19 (Supp. 1): 113-117
em Inglês
| IMEMR
| ID: emr-189347
ABSTRACT
The detection of KRAS and BRAF mutations is a crucial step for the correct therapeutic approach and predicting the epidermal growth factor receptor [EGFR]-targeted therapy resistance of colorectal carcinomas. The concomitant KRAS and BRAF mutations occur rarely in the colorectal cancers [CRCs] with the prevalence of less than 0.001% of the cases. In patients with KRAS-mutant tumors, BRAF mutations should not regularly be tested unless the patient is participating in a clinical trial enriching for the presence of KRAS or BRAF-mutated tumor. The current report demonstrates a case with advanced adenocarcinoma of the colon showing the coexistence of KRAS and BRAF mutations and may have profound clinical implications for disease progression and therapeutic responses
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
Adenocarcinoma
/
Proteínas Proto-Oncogênicas p21(ras)
/
Proteínas Proto-Oncogênicas B-raf
/
Receptores ErbB
/
Mutação
Tipo de estudo:
Relato de Casos
Limite:
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Cell J. [Yakhteh]
Ano de publicação:
2017
Similares
MEDLINE
...
LILACS
LIS